Read by QxMD icon Read

rashed m shah

Jorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D le Coutre, Ronald Paquette, Charles Chuah, Franck E Nicolini, Jane F Apperley, H Jean Khoury, Moshe Talpaz, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M Rivera, Frank G Haluska, François Guilhot, Michael W Deininger, Andreas Hochhaus, Timothy P Hughes, Neil P Shah, Hagop M Kantarjian
Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I The pivotal phase 2 PACE trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia resistant/intolerant to dasatinib or nilotinib, or with BCR ABL1T315I This analysis focuses on chronic-phase CML (CP-CML) patients (n=270) with 56.8-month median follow-up. Among 267 evaluable patients, 60%, 40%, and 24% achieved major cytogenetic response (MCyR), major molecular response (MMR), and MR4...
March 22, 2018: Blood
Abhishek Maiti, Maryam Nemati-Shafaee, Pavlos Msaouel, Lance C Pagliaro, Eric Jonasch, Nizar M Tannir, Amishi Y Shah
BACKGROUND: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. PATIENTS AND METHODS: Patients with metastatic or unresectable sRCC were eligible for inclusion. Patients received oral capecitabine 800 mg/m2 twice daily on days 1 to 21 of a 28-day cycle, intravenous gemcitabine 900 mg/m2 on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15...
August 10, 2017: Clinical Genitourinary Cancer
D Rashed, D Shah, A Freeman, R J Cook, C Hopper, C M Perrett
BACKGROUND: Mohs micrographic surgery (MMS) is an effective treatment for certain non-melanoma skin cancers. Optical coherence tomography (OCT) is a biomedical imaging modality that permits high-resolution imaging of the epidermis and dermis with the potential to detect both healthy tissue and tumour. OCT may also provide a means of detecting and differentiating between the various histological subtypes of basal cell carcinomas (BCC) in vivo. OBJECTIVE: The aim of this prospective ex vivo study was to evaluate the efficacy of OCT in recognising healthy and pathological margins of excised BCC lesions and detecting different BCC subtypes...
September 2017: Photodiagnosis and Photodynamic Therapy
M Shah
It is important to assess outcomes for medical interventions in order to focus scarce resources on outcomes with a known positive benefit. An open, observational study was performed to assess the clinical outcomes of 600 male patients with a genital skin problem attending a specialist secondary care dermatology facility. Patients were mainly referred by general practitioners and genitourinary medicine physicians. Outcome was measured at 3 and 6 months, and was determined by clinical examination and assessment of patient symptoms...
October 2017: Clinical and Experimental Dermatology
Luke C Mullany, Shams El Arifeen, Subarna K Khatry, Joanne Katz, Rashed Shah, Abdullah H Baqui, James M Tielsch
Guidance is needed regarding potential extension of the World Health Organization recommendation for cord cleansing with chlorhexidine to babies born in facilities. Among 3223 facility-born babies from Nepal and Bangladesh, mortality was approximately halved among those allocated to the intervention clusters [10.5/1000 vs. 19.4/1000; relative risk (RR): 0.54; 95% confidence interval: 0.30-0.97]. In high-mortality settings, a single policy for home and facility births is warranted.
October 2017: Pediatric Infectious Disease Journal
Shah M Rashed, Nur A Hasan, Munirul Alam, Abdus Sadique, Marzia Sultana, Md Mozammel Hoq, R Bradley Sack, Rita R Colwell, Anwar Huq
Cholera outbreaks occur each year in the remote coastal areas of Bangladesh and epidemiological surveillance and routine monitoring of cholera in these areas is challenging. In this study, a total of 97 Vibrio cholerae O1 isolates from Mathbaria, Bangladesh, collected during 2010 and 2014 were analyzed for phenotypic and genotypic traits, including antimicrobial susceptibility. Of the 97 isolates, 95 possessed CTX-phage mediated genes, ctxA, ace, and zot, and two lacked the cholera toxin gene, ctxA. Also both CTX(+) and CTX(-)V...
2017: Frontiers in Microbiology
Thaker A A Alyousefi, Rashad Abdul-Ghani, Mohammed A K Mahdy, Samira M A Al-Eryani, Abdulsalam M Al-Mekhlafi, Yahia A Raja, Shamusul Azhar Shah, John C Beier
BACKGROUND: Yemen has witnessed several dengue fever outbreaks coincident with the social unrest and war in the country. The aim of the present study was to describe the knowledge, attitudes and practices (KAPs) of at-risk urban populations residing in Taiz, southwest of Yemen. In addition, factors possibly associated with poor preventive practices were investigated. METHODS: A household-based, cross-sectional survey was conducted in three urban districts encompassing 383 households...
October 7, 2016: BMC Infectious Diseases
Stephanie Mlacker, Golsa Shafa, Adam S Aldahan, Vidhi V Shah, Sahal Samarkandy, Keyvan Nouri
BACKGROUND: Zika virus (ZIKV) is an arbovirus within the Flaviviridae family, the recent spread of which has promoted public concern. METHODS: This study outlines the clinical features, potential for teratogenicity, diagnosis, and treatment of ZIKV infection. RESULTS: Zika virus is transmitted through the bite of an infected Stegomyia (= Aedes) mosquito, blood transfusion, sexual intercourse, and perinatal routes. Infection has been characterized as mildly symptomatic...
December 2016: International Journal of Dermatology
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, Franck E Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian Oehler, Stephanie Lustgarten, Victor M Rivera, Timothy Clackson, Frank G Haluska, Michele Baccarani, Jorge E Cortes, François Guilhot, Andreas Hochhaus, Timothy Hughes, Hagop M Kantarjian, Neil P Shah, Moshe Talpaz, Michael W Deininger
BACKGROUND: Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated with arterial occlusion. We investigated whether this activity and safety profile would result in superior outcomes compared with imatinib in previously untreated patients with chronic myeloid leukaemia. METHODS: The Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia (EPIC) study was a randomised, open-label, phase 3 trial designed to assess the efficacy and safety of ponatinib, compared with imatinib, in newly diagnosed patients with chronic-phase chronic myeloid leukaemia...
May 2016: Lancet Oncology
Seon Young Choi, Shah M Rashed, Nur A Hasan, Munirul Alam, Tarequl Islam, Abdus Sadique, Fatema-Tuz Johura, Mark Eppinger, Jacques Ravel, Anwar Huq, Alejandro Cravioto, Rita R Colwell
UNLABELLED: An outbreak of cholera occurred in 1991 in Mexico, where it had not been reported for more than a century and is now endemic. Vibrio cholerae O1 prototype El Tor and classical strains coexist with altered El Tor strains (1991 to 1997). Nontoxigenic (CTX(-)) V. cholerae El Tor dominated toxigenic (CTX(+)) strains (2001 to 2003), but V. cholerae CTX(+) variant El Tor was isolated during 2004 to 2008, outcompeting CTX(-) V. cholerae. Genomes of six Mexican V. cholerae O1 strains isolated during 1991 to 2008 were sequenced and compared with both contemporary and archived strains of V...
March 15, 2016: MBio
H Roger Brown, Stephen Castellino, M Reid Groseclose, Chandikumar S Elangbam, Kathryn Mellon-Kusibab, Lawrence W Yoon, Lisa D Gates, David L Krull, Neal F Cariello, Leigh Arrington-Brown, Tony Tillman, Serita Fowler, Vishal Shah, David Bailey, Richard T Miller
Nevirapine (NVP) is associated with hepatotoxicity in 1-5% of patients. In rodent studies, NVP has been shown to cause hepatic enzyme induction, centrilobular hypertrophy, and skin rash in various rat strains but not liver toxicity. In an effort to understand whether NVP is metabolized differently in a transiently inflamed liver and whether a heightened immune response alters NVP-induced hepatic responses, female brown Norway rats were dosed with either vehicle or NVP alone (75 mg/kg/day for 15 days) or galactosamine alone (single intraperitoneal [ip] injection on day 7 to mimic viral hepatitis) or a combination of NVP (75/100/150 mg/kg/day for 15 days) and galactosamine (single 750 mg/kg ip on day 7)...
January 2016: Toxicologic Pathology
Ruben Magni, Benjamin H Espina, Ketul Shah, Benjamin Lepene, Christine Mayuga, Temple A Douglas, Virginia Espina, Sally Rucker, Ross Dunlap, Emanuel F Iii Petricoin, Mary Frekko Kilavos, Donald M Poretz, Gilbert R Irwin, Samuel M Shor, Lance A Liotta, Alessandra Luchini
OBJECTIVES: Prompt antibiotic treatment of early stage Lyme borreliosis (LB) prevents progression to severe multisystem disease. There is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior to the mounting of a robust serology response. Using a novel analyte harvesting nanotechnology, Nanotrap particles, we evaluated urinary Borrelia Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after treatment, and in patients suspected of late stage disseminated LB...
November 4, 2015: Journal of Translational Medicine
Jia Ruan, Peter Martin, Bijal Shah, Stephen J Schuster, Sonali M Smith, Richard R Furman, Paul Christos, Amelyn Rodriguez, Jakub Svoboda, Jessica Lewis, Orel Katz, Morton Coleman, John P Leonard
BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy. METHODS: We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase...
November 5, 2015: New England Journal of Medicine
Daniel E Roth, Alison D Gernand, Shaun K Morris, Brendon Pezzack, M Munirul Islam, Michelle C Dimitris, Shaila S Shanta, Stanley H Zlotkin, Andrew R Willan, Tahmeed Ahmed, Prakesh S Shah, Kellie E Murphy, Rosanna Weksberg, Sanaa Choufani, Rashed Shah, Abdullah Al Mahmud
BACKGROUND: Vitamin D regulates bone mineral metabolism and skeletal development. Some observational studies have suggested that prenatal vitamin D deficiency increases the risk of adverse pregnancy and/or birth outcomes; however, there is scant evidence from controlled trials, leading the World Health Organization to advise against routine vitamin D supplementation in pregnancy. Importantly, little is known about the effect of maternal vitamin D status on infant linear growth in communities in South Asia where stunting is highly prevalent and maternal-infant vitamin D status is commonly suboptimal...
2015: Trials
Michael M Givertz, Kevin J Anstrom, Margaret M Redfield, Anita Deswal, Haissam Haddad, Javed Butler, W H Wilson Tang, Mark E Dunlap, Martin M LeWinter, Douglas L Mann, G Michael Felker, Christopher M O'Connor, Steven R Goldsmith, Elizabeth O Ofili, Mitchell T Saltzberg, Kenneth B Margulies, Thomas P Cappola, Marvin A Konstam, Marc J Semigran, Steven E McNulty, Kerry L Lee, Monica R Shah, Adrian F Hernandez
BACKGROUND: Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes. METHODS AND RESULTS: We randomly assigned 253 patients with symptomatic HF, left ventricular ejection fraction ≤40%, and serum uric acid levels ≥9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a double-blind, multicenter trial. The primary composite end point at 24 weeks was based on survival, worsening HF, and patient global assessment...
May 19, 2015: Circulation
David C Klinzing, Seon Young Choi, Nur A Hasan, Ronald R Matias, Enrique Tayag, Josefina Geronimo, Evan Skowronski, Shah M Rashed, Kent Kawashima, C Nicole Rosenzweig, Henry S Gibbons, Brian C Torres, Veni Liles, Alicia C Alfon, Maria Luisa Juan, Filipinas F Natividad, Thomas A Cebula, Rita R Colwell
UNLABELLED: Cholera continues to be a global threat, with high rates of morbidity and mortality. In 2011, a cholera outbreak occurred in Palawan, Philippines, affecting more than 500 people, and 20 individuals died. Vibrio cholerae O1 was confirmed as the etiological agent. Source attribution is critical in cholera outbreaks for proper management of the disease, as well as to control spread. In this study, three V. cholerae O1 isolates from a Philippines cholera outbreak were sequenced and their genomes analyzed to determine phylogenetic relatedness to V...
2015: MBio
Rahman Shah, M Rehan Khan, Tai-Hwang M Fan, Genina Ruff, Kodangudi B Ramanathan
An 81-year-old man presented with a 1-week history of dry cough. He also complained of mild dyspnea, wheezing, and low-grade fever. He denied hemoptysis, fever, rashes, or chest pain. The patient's medical history included coronary artery bypass surgery, hypertension, gastroesophageal reflux disease, and COPD. The patient was a retired welder and an ex-smoker.
February 2015: Chest
Daniela Ceccarelli, Arlene Chen, Nur A Hasan, Shah M Rashed, Anwar Huq, Rita R Colwell
Non-O1/non-O139 Vibrio cholerae inhabits estuarine and coastal waters globally, but its clinical significance has not been sufficiently investigated, despite the fact that it has been associated with septicemia and gastroenteritis. The emergence of virulent non-O1/non-O139 V. cholerae is consistent with the recognition of new pathogenic variants worldwide. Oyster, sediment, and water samples were collected during a vibrio surveillance program carried out from 2009 to 2012 in the Chesapeake Bay, Maryland. V...
March 2015: Applied and Environmental Microbiology
Catherine Lombard-Bohas, James C Yao, Timothy Hobday, Eric Van Cutsem, Edward M Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H Shah, Jaume Capdevila, Rodney Pommier
OBJECTIVE: The aim of this study was to evaluate efficacy and safety of everolimus in patients with pancreatic neuroendocrine tumors (pNET) by prior chemotherapy use in the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3). METHODS: Patients with advanced, progressive, low- or intermediate-grade pNET were prospectively stratified by prior chemotherapy use and World Health Organization performance status and were randomly assigned (1:1) to everolimus 10 mg/d (n = 207) or placebo (n = 203)...
March 2015: Pancreas
Nathan H Fowler, R Eric Davis, Seema Rawal, Loretta Nastoupil, Fredrick B Hagemeister, Peter McLaughlin, Larry W Kwak, Jorge E Romaguera, Michelle A Fanale, Luis E Fayad, Jason R Westin, Jatin Shah, Robert Z Orlowski, Michael Wang, Francesco Turturro, Yasuhiro Oki, Linda C Claret, Lei Feng, Veerabhadran Baladandayuthapani, Tariq Muzzafar, Kenneth Y Tsai, Felipe Samaniego, Sattva S Neelapu
BACKGROUND: Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma. We assessed the efficacy and safety of lenalidomide plus rituximab in patients with untreated, advanced stage indolent non-Hodgkin lymphoma. METHODS: In this phase 2 trial, undertaken at one instution, patients with follicular lymphoma and marginal zone lymphoma were given lenalidomide, orally, at 20 mg/day on days 1-21 of each 28-day cycle...
November 2014: Lancet Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"